Evidence map›Paper›PMID 40315290›Full record

Observational studyPloS one2025

Bacterial profile, treatment outcomes, and determinants among adult patients with musculoskeletal infections admitted to Jimma Medical Center: A prospective observational study.

Desalegn Gizaw, Gorfineh Teshome, Kisi Chemeda, Aster Wakjira, Mekonnen Damessa

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Desalegn GizawDepartment of Clinical Pharmacy, Jimma University, Institute of Health, Jimma, Ethiopia.
Gorfineh TeshomeDepartment of Clinical Pharmacy, Jimma University, Institute of Health, Jimma, Ethiopia.ORCID https://orcid.org/0009-0002-1807-5820
Kisi ChemedaDepartment of Clinical Pharmacy, Jimma University, Institute of Health, Jimma, Ethiopia.ORCID https://orcid.org/0009-0003-5283-3821
Aster WakjiraDepartment of Clinical Pharmacy, Jimma University, Institute of Health, Jimma, Ethiopia.
Mekonnen DamessaDepartment of Clinical Pharmacy, Jimma University, Institute of Health, Jimma, Ethiopia.ORCID https://orcid.org/0000-0002-0740-6113

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe epidemiological characteristics of musculoskeletal infections are constantly evolving. Despite the significant burden of musculoskeletal infections in sub-Saharan Africa, there is a scarcity of data regarding the potential causes and treatment outcomes of such infections in the region. Therefore, the primary objective of this study was to assess a management protocol, clinical outcomes, and associated factors among adult individuals diagnosed with musculoskeletal infections.

methodsAdult patients admitted to Jimma University Medical Center (JUMC), Ethiopia with a diagnosis of musculoskeletal infections was enrolled prospectively from July 2022-December 2022. Clinical characteristics, management protocol, and complications were recorded from admission to discharge. Bacteria were identified by a series of biochemical tests, and antimicrobial susceptibility testing was performed using the Kirby-Bauer Disk diffusion method. Data were analyzed by using SPSS v.23 and the p-value <0.05 was considered statistically significant.

resultAmong 160 participants included in the study, 103(64.37%) were male, and the mean age 33.51 ± 13.56 years. About 94 (58.8%) of patients had microbial growth, of which 75.5% accounts for mono-microbial. The common bacterial isolates were Staphylococcus aureus in (22.4%), Escherichia coli (18.1%), Pseudomonas aeruginosa (14.7) and Klebsiella pneumonia (11.2). The isolated etiologies were resistant to Ceftriaxone in 67(81.70%) and Ceftazidime in 47(61.8%) of test results. Nearly all (98.8%) of patients were took antibiotics on admission and Ceftriaxone was highly utilized as monotherapy in (23.4%) of patients. Nearly half (46.9%) of the patients were develop treatment failure. Sex [AOR = 2.56, 95%CI (1.07-6.23)], microbial growth [AOR = 3.03, 95%CI (1.31-6.97)], ceftriaxone resistance [AOR = 4.46, 95%CI (1.06-18.67)], co-morbidities [AOR = 2.32, 95%CI (1.007-5.36)], and complications [AOR = 2.80, 95%CI (1.26-6.20)] were associated with treatment failure outcome.

conclusionClose to half of adult patients with musculoskeletal infections experienced treatment failure. Staphylococcus aureus stood out as the prevailing bacterial strain identified. The timely switching of parenteral antibiotics to oral counterparts, alongside timely surgical interventions, significantly enhanced the recovery outcomes for these individuals.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsMusculoskeletal DiseasesAdultBacteriaEthiopiaFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedProspective StudiesTreatment OutcomeYoung AdultAnti-Bacterial Agents

Identifiers

PMID40315290
PMCPMC12047840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.